ClinicalTrials.gg
CompletedNCT01710046Updated Apr 13, 2015Results posted

Study Of The Mechanism Of Action Of CP-690,550 In The Skin Of Subjects With Moderate To Severe Chronic Plaque Psoriasis

A Phase 2 interventional study of (CP-6890,550) Tofacitinib and Placebo in Plaque Psoriasis, sponsored by Pfizer. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-04-13.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 19 studies testing tofacitinib in Psoriasis — 4 open to participants now, 4 under way, 1 of them phase 3. tofacitinib · Psoriasis.

Enrollment
18th of 19
12 · median 135
Started
2013
with 2 others
Phase 2
6 of 19
none open now
Registered
10th of 19
by date
Lead sponsor
14 of 19
Pfizer

Among the 19 studies testing tofacitinib in Psoriasis, this one is the 18th largest by enrollment, is one of 3 that started in 2013, is one of 6 in phase 2, and was the 10th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

4 of the 19 studies testing tofacitinib in Psoriasis are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About tofacitinib

tofacitinib: first FDA approval 2012 (XELJANZ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing tofacitinib in Psoriasis, or all of them as a file.
02

Study summary

There are cells in the skin and blood of humans with chronic moderate to severe plaque psoriasis with specific activities that may determine the effectiveness of treatment. These activities may be described by obtaining samples of skin and blood and analyzing them using a variety of tests.

Read the detailed description

The final subject in Cohort 1 completed the study on 19-Nov-2013 (LSLV date). Because the study analyses were novel and exploratory, they required extensive analyses by study team and external experts. As a result of this analysis it was determined on 21-July-2014 that the data from Cohort 1 were sufficiently definitive and that enrollment of Cohort 2 would not be justified. Since this decision resulted in the LSLV for Cohort 1 becoming the LSLV for the study, the full data analysis and reporting is not projected to be complete within 12 Months of LSLV. The final analysis and final reporting is planned to be completed on 18-Feb-2015. Results for this data are anticipated to be released in April 2015.

03

Conditions studied

  • Plaque Psoriasis

Browse trials for

Keywords

  • plaque psoriasis
  • tofacitinib
  • biopsy
  • Janus Kinase
  • randomized placebo controlled clinical trial
  • psoriasis vulgaris
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults over 18 years of age with a diagnosis of chronic moderate to severe plaque psoriasis for at least 12 months; in generally good health; on stable dose of non-prohibited medications; able to stop current psoriasis therapy (systemic or topical) for several weeks prior to and during study participation.

Exclusion criteria

Exclusion Criteria:

  • Serious underlying disease including viral disorders such as hepatitis or or skin condition that would interfere with skin or evaluation of psoriasis; conditions that could interfere with drug absorption after oral administration; history of or auto-immune disease.
  • Use of oral or injected (steroids).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Drug: (CP-6890,550) Tofacitinib · Drug: Placebo

  • Experimental
    Cohort 2

    Drug: (CP-690,550) Tofacitinib · Drug: Placebo

Interventions

  • 2 x 5 mg oral capsules taken twice daily (every 12 hours) for 12 consecutive weeks

  • DrugPlacebo

    2 matching oral capsules taken twice daily (every 12 hours) for 12 consecutive weeks

  • 2 x 5 mg oral capsules taken twice daily (every 12 hours) for 12 weeks

  • DrugPlacebo

    2 matching oral capsules taken twice daily (every 12 hours) for 12 consecutive weeks

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving a 75% Reduction in the Psoriasis Area and Severity Index (PASI75) at Week 12

    Combined assessment of lesion severity and area affected into single score; range equals (=) 0 (no disease) to 72 (maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated: 0 (0%) to 6 (90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4) summed over all sections.

    Time frame: Week 12

  2. Percentage of Participants Achieving a Physician's Global Assessment (PGA) Response of "Clear" or "Almost Clear" at Week 12

    PGA psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration and scaling across all psoriatic lesions. PGA of Psoriasis scale ranges from 0 (no psoriasis) to 4 (severe disease). ‘Clear’ and “Almost clear’ includes all participants who were scored as a 0 or 1.

    Time frame: Week 12

Secondary outcomes

  1. Psoriasis Area and Severity Index (PASI) Score by Visit

    Combined assessment of lesion severity and area affected into single score. Body was divided into 4 sections: head, arms, trunk, legs. For each section, percent area of skin involved was estimated: 0=0% to 6=90â€"100%. Severity was estimated by clinical signs: erythema, induration, desquamation; scale: 0= none to 4= maximum. Final PASI = sum of severity parameters for each section\*area score\*weight of section (head: 0.1, arms: 0.2, body: 0.3, legs: 0.4) summed over all sections; total possible score range: 0= no disease to 72= maximal disease.

    Time frame: Baseline and Weeks 1, 2, 4, and 12

  2. Change From Baseline in PASI by Visit

    Combined assessment of lesion severity and area affected into single score. Body was divided into 4 sections: head, arms, trunk, legs. For each section, percent area of skin involved was estimated: 0=0% to 6=90â€"100%. Severity was estimated by clinical signs: erythema, induration, desquamation; scale: 0= none to 4= maximum. Final PASI = sum of severity parameters for each section\*area score\*weight of section (head: 0.1, arms: 0.2, body: 0.3, legs: 0.4) summed over all sections; total possible score range: 0= no disease to 72= maximal disease.

    Time frame: Weeks 1, 2, 4 and 12

  3. Percent Change From Baseline in PASI by Visit

    Combined assessment of lesion severity and area affected into single score. Body was divided into 4 sections: head, arms, trunk, legs. For each section, percent area of skin involved was estimated: 0= 0% to 6= 90â€"100%. Severity was estimated by clinical signs: erythema, induration, desquamation; scale: 0= none to 4= maximum. Final PASI = sum of severity parameters for each section\*area score\*weight of section (head: 0.1, arms: 0.2, body: 0.3, legs: 0.4) summed over all sections; total possible score range: 0= no disease to 72= maximal disease.

    Time frame: Weeks 1, 2, 4, and 12

  4. Percentage of Participants Achieving a PASI75 Response at Weeks 1, 2, and 4

    Combined assessment of lesion severity and area affected into single score; range=0 (no disease) to 72 (maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated: 0 (0%) to 6 (90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4) summed over all sections.

    Time frame: Weeks 1, 2, and 4

  5. Change From Baseline in PGA Score by Visit

    PGA psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. PGA of Psoriasis scale ranges from 0 (no psoriasis) to 4 (severe disease). The severity scores of 3 components (erythema, induration, and scaling) are averaged and rounded to the nearest whole number to determine the PGA score.

    Time frame: Weeks 1, 2, 4, and 12

  6. Percentage of Participants in Each PGA Category at Various Timepoints by Baseline Category

    Time frame: Baseline and Weeks 1, 2, 4, and 12

  7. Percentage of Participants by PGA Response Category and Timepoint

    PGA psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration and scaling across all psoriatic lesions. PGA of Psoriasis scale ranges from 0 (no psoriasis) to 4 (severe disease). Response category scores: 0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe. The severity scores of 3 components (erythema, induration, and scaling) are averaged and rounded to the nearest whole number to determine the PGA score.

    Time frame: Baseline and Weeks 1, 2, 4, and 12

  8. Body Surface Area (BSA)

    Assessment of BSA with psoriasis was performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The percent surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (ie, the participant's fully extended palm, fingers and thumb together) represents approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region can be used to determine the extent (%) to which a body regions is involved with psoriasis. In each body region, the percent body region surface area with psoriasis is multiplied by the Body Region Weighting (head and neck=10%, upper limbs=5%, trunk \[including axillae and groin\]=3.33% and lower limbs \[including buttocks\]=2.5%). BSA (%)=0.1Sh + 0.2Sh+0.3St+0.4Sl, where S=body region suface area with psoriasis: h=head; u=upper limbs; t=trunk; l=lower limbs.

    Time frame: Baseline and Weeks 1, 2, 4, and 12

  9. Change From Baseline in BSA

    Assessment of BSA with psoriasis was performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The percent surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (ie, the participant's fully extended palm, fingers and thumb together) represents approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region can be used to determine the extent (%) to which a body regions is involved with psoriasis. In each body region, the percent body region surface area with psoriasis is multiplied by the Body Region Weighting (head and neck=10%, upper limbs=5%, trunk \[including axillae and groin\]=3.33% and lower limbs \[including buttocks\]=2.5%). BSA (%)=0.1Sh + 0.2Sh+0.3St+0.4Sl, where S=body region suface area with psoriasis: h=head; u=upper limbs; t=trunk; l=lower limbs.

    Time frame: Weeks 1, 2, 4, and 12

  10. Percent Change From Baseline in BSA

    Assessment of BSA with psoriasis was performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The percent surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (ie, the participant's fully extended palm, fingers and thumb together) represents approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region can be used to determine the extent (%) to which a body regions is involved with psoriasis. In each body region, the percent body region surface area with psoriasis is multiplied by the Body Region Weighting (head and neck=10%, upper limbs=5%, trunk \[including axillae and groin\]=3.33% and lower limbs \[including buttocks\]=2.5%). BSA (%)=0.1Sh + 0.2Sh+0.3St+0.4Sl, where S=body region suface area with psoriasis: h=head; u=upper limbs; t=trunk; l=lower limbs.

    Time frame: Weeks 1, 2, 4, and 12

  11. Itch Severity Item (ISI) Score by Visit

    The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single-item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends. the baseline is defined as the average of all available diary entries before Baseline/Day 1 and the in-clinic measurement on Baseline/day 1. Week 1 is the mean of daily values of study days 2 to 8 and Week 2 is the mean of daily values of study days 9 to 15.

    Time frame: Baseline and Weeks 1, 2, 4, and 12

  12. Change From Baseline in ISI by Visit

    ISI, a single-item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends. The baseline is defined as the average of all available diary entries before Baseline/Day 1 and the in-clinic measurement on Baseline/Day 1. Week 1 is the mean of daily values of study days 2 to 8 and Week 2 is the mean of daily values of study days 9 to 15. A negative value indicates an improvement.

    Time frame: Weeks 1, 2, 4 and 12

  13. Target Plaque Severity Score (TPSS) by Visit

    Target lesions were selected at baseline and followed for the duration of the study. Each target lesion was scored by the investigator on severity of erythema, induration, and scaling according to a 5-point (0 to 4) severity scale with a maximum sum score for a plaque of 12. The TPSS was calculated as the sum of the scores for erythema, induration, and scaling; the score can vary in increments of 1 unit from 0 to 12.

    Time frame: Baseline and Weeks 1, 2, 4, and 12

  14. Percent Change From Baseline in TPSS by Visit

    Target lesions were selected at baseline and followed for the duration of the study. Each target lesion was scored by the investigator on severity of erythema, induration, and scaling according to a 5-point (0 to 4) severity scale with a maximum sum score for a plaque of 12. The TPSS was calculated as the sum of the scores for erythema, induration, and scaling; the score can vary in increments of 1 unit from 0 to 12. A negative value indicated improvment.

    Time frame: Weeks 1, 2, 4, and 12

07

Results

Posted Apr 13, 2015

Participant flow

Participant flow — Overall Study
MilestoneTofacitinib 10 Milligrams (mg) Twice Daily (BID)Placebo
Started93
Completed83
Not completed10
Withdrew: Lost to follow-up10

Outcome measures

PrimaryPercentage of Participants Achieving a 75% Reduction in the Psoriasis Area and Severity Index (PASI75) at Week 12

Combined assessment of lesion severity and area affected into single score; range equals (=) 0 (no disease) to 72 (maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated: 0 (0%) to 6 (90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4) summed over all sections.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a 75% Reduction in the Psoriasis Area and Severity Index (PASI75) at Week 12
percentage of participantsTofacitinib 10 mg BIDPlacebo
Percentage of Participants Achieving a 75% Reduction in the Psoriasis Area and Severity Index (PASI75) at Week 1262.5033.33
PrimaryPercentage of Participants Achieving a Physician's Global Assessment (PGA) Response of "Clear" or "Almost Clear" at Week 12

PGA psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration and scaling across all psoriatic lesions. PGA of Psoriasis scale ranges from 0 (no psoriasis) to 4 (severe disease). ‘Clear’ and “Almost clear’ includes all participants who were scored as a 0 or 1.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Physician's Global Assessment (PGA) Response of "Clear" or "Almost Clear" at Week 12
percentage of participantsTofacitinib 10 mg BIDPlacebo
Percentage of Participants Achieving a Physician's Global Assessment (PGA) Response of "Clear" or "Almost Clear" at Week 1250.0033.33
SecondaryPsoriasis Area and Severity Index (PASI) Score by Visit

Combined assessment of lesion severity and area affected into single score. Body was divided into 4 sections: head, arms, trunk, legs. For each section, percent area of skin involved was estimated: 0=0% to 6=90â€"100%. Severity was estimated by clinical signs: erythema, induration, desquamation; scale: 0= none to 4= maximum. Final PASI = sum of severity parameters for each section\*area score\*weight of section (head: 0.1, arms: 0.2, body: 0.3, legs: 0.4) summed over all sections; total possible score range: 0= no disease to 72= maximal disease.

Time frame:
Baseline and Weeks 1, 2, 4, and 12
Reported as:
Mean · units on a scale
Psoriasis Area and Severity Index (PASI) Score by Visit
units on a scaleTofacitinib 10 mg BIDPlacebo
Baseline (n=9,3)21.91 ± 2.8623.33 ± 5.67
Week 1 (n=9,3)17.81 ± 3.1015.53 ± 6.60
Week 2 (n=9,3)13.84 ± 2.7113.13 ± 6.27
Week 4 (n=9,3)11.72 ± 3.5113.37 ± 6.05
Week 12 (n=8,3)5.80 ± 1.8013.40 ± 6.12
SecondaryChange From Baseline in PASI by Visit

Combined assessment of lesion severity and area affected into single score. Body was divided into 4 sections: head, arms, trunk, legs. For each section, percent area of skin involved was estimated: 0=0% to 6=90â€"100%. Severity was estimated by clinical signs: erythema, induration, desquamation; scale: 0= none to 4= maximum. Final PASI = sum of severity parameters for each section\*area score\*weight of section (head: 0.1, arms: 0.2, body: 0.3, legs: 0.4) summed over all sections; total possible score range: 0= no disease to 72= maximal disease.

Time frame:
Weeks 1, 2, 4 and 12

No measurements were reported for this outcome.

SecondaryPercent Change From Baseline in PASI by Visit

Combined assessment of lesion severity and area affected into single score. Body was divided into 4 sections: head, arms, trunk, legs. For each section, percent area of skin involved was estimated: 0= 0% to 6= 90â€"100%. Severity was estimated by clinical signs: erythema, induration, desquamation; scale: 0= none to 4= maximum. Final PASI = sum of severity parameters for each section\*area score\*weight of section (head: 0.1, arms: 0.2, body: 0.3, legs: 0.4) summed over all sections; total possible score range: 0= no disease to 72= maximal disease.

Time frame:
Weeks 1, 2, 4, and 12
Reported as:
Mean · percent change from baseline
Percent Change From Baseline in PASI by Visit
percent change from baselineTofacitinib 10 mg BIDPlacebo
Week 1 (n=9,3)-18.38 ± 7.52-39.61 ± 19.97
Week 2 (n=9,3)-36.95 ± 8.28-48.66 ± 20.28
Week 4 (n=9,3)-47.39 ± 11.95-49.66 ± 19.41
Week 12 (n=8,3)-71.78 ± 9.63-49.13 ± 19.67
SecondaryPercentage of Participants Achieving a PASI75 Response at Weeks 1, 2, and 4

Combined assessment of lesion severity and area affected into single score; range=0 (no disease) to 72 (maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated: 0 (0%) to 6 (90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4) summed over all sections.

Time frame:
Weeks 1, 2, and 4
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a PASI75 Response at Weeks 1, 2, and 4
percentage of participantsTofacitinib 10 mg BIDPlacebo
Week 10.000.00
Week 20.0033.33
Week 422.2233.33
SecondaryChange From Baseline in PGA Score by Visit

PGA psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. PGA of Psoriasis scale ranges from 0 (no psoriasis) to 4 (severe disease). The severity scores of 3 components (erythema, induration, and scaling) are averaged and rounded to the nearest whole number to determine the PGA score.

Time frame:
Weeks 1, 2, 4, and 12
Reported as:
Mean · units on a scale
Change From Baseline in PGA Score by Visit
units on a scaleTofacitinib 10 mg BIDPlacebo
Week 1 (n=9,3)-0.6 ± 0.2-0.7 ± 0.3
Week 2 (n=9,3)-0.8 ± 0.2-1.0 ± 0.6
Week 4 (n=9,3)-1.2 ± 0.3-1.0 ± 0.6
Week 12 (n=8,3)-1.5 ± 0.3-1.0 ± 0.6
SecondaryPercentage of Participants in Each PGA Category at Various Timepoints by Baseline Category
Time frame:
Baseline and Weeks 1, 2, 4, and 12

No measurements were reported for this outcome.

SecondaryPercentage of Participants by PGA Response Category and Timepoint

PGA psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration and scaling across all psoriatic lesions. PGA of Psoriasis scale ranges from 0 (no psoriasis) to 4 (severe disease). Response category scores: 0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe. The severity scores of 3 components (erythema, induration, and scaling) are averaged and rounded to the nearest whole number to determine the PGA score.

Time frame:
Baseline and Weeks 1, 2, 4, and 12
Reported as:
Number · percentage of participants
Percentage of Participants by PGA Response Category and Timepoint
percentage of participantsTofacitinib 10 mg BIDPlacebo
Baseline, Moderate (n=9,3)88.966.7
Baseline, Severe (n=9,3)11.133.3
Week 1, Mild (n=9,3)44.433.3
Week 1, Moderate (n=9,3)55.666.7
Week 2, Almost clear (n=9,3)11.133.3
Week 2, Mild (n=9,3)44.40
Week 2, Moderate (n=9,3)44.466.7
Week 4, Almost clear (n=9,3)44.433.3
Week 4, Mild (n=9,3)22.20
Week 4, Moderate (n=9,3)33.366.7
Week 12, Almost clear (n=8,3)50.033.3
Week 12, Mild (n=8,3)37.50
Week 12, Moderate (n=8,3)12.566.7
SecondaryBody Surface Area (BSA)

Assessment of BSA with psoriasis was performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The percent surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (ie, the participant's fully extended palm, fingers and thumb together) represents approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region can be used to determine the extent (%) to which a body regions is involved with psoriasis. In each body region, the percent body region surface area with psoriasis is multiplied by the Body Region Weighting (head and neck=10%, upper limbs=5%, trunk \[including axillae and groin\]=3.33% and lower limbs \[including buttocks\]=2.5%). BSA (%)=0.1Sh + 0.2Sh+0.3St+0.4Sl, where S=body region suface area with psoriasis: h=head; u=upper limbs; t=trunk; l=lower limbs.

Time frame:
Baseline and Weeks 1, 2, 4, and 12
Reported as:
Mean · % BSA
Body Surface Area (BSA)
% BSATofacitinib 10 mg BIDPlacebo
Baseline (n=9,3)34.16 ± 8.1230.50 ± 10.87
Week 1 (n=9,3)31.20 ± 7.3524.83 ± 10.43
Week 2 (n=9,3)24.20 ± 5.3824.67 ± 10.59
Week 4 (n=9,3)19.03 ± 4.7023.33 ± 10.43
Week 12 (n=8,3)7.35 ± 3.1023.03 ± 10.50
SecondaryChange From Baseline in BSA

Assessment of BSA with psoriasis was performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The percent surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (ie, the participant's fully extended palm, fingers and thumb together) represents approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region can be used to determine the extent (%) to which a body regions is involved with psoriasis. In each body region, the percent body region surface area with psoriasis is multiplied by the Body Region Weighting (head and neck=10%, upper limbs=5%, trunk \[including axillae and groin\]=3.33% and lower limbs \[including buttocks\]=2.5%). BSA (%)=0.1Sh + 0.2Sh+0.3St+0.4Sl, where S=body region suface area with psoriasis: h=head; u=upper limbs; t=trunk; l=lower limbs.

Time frame:
Weeks 1, 2, 4, and 12

No measurements were reported for this outcome.

SecondaryPercent Change From Baseline in BSA

Assessment of BSA with psoriasis was performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The percent surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (ie, the participant's fully extended palm, fingers and thumb together) represents approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region can be used to determine the extent (%) to which a body regions is involved with psoriasis. In each body region, the percent body region surface area with psoriasis is multiplied by the Body Region Weighting (head and neck=10%, upper limbs=5%, trunk \[including axillae and groin\]=3.33% and lower limbs \[including buttocks\]=2.5%). BSA (%)=0.1Sh + 0.2Sh+0.3St+0.4Sl, where S=body region suface area with psoriasis: h=head; u=upper limbs; t=trunk; l=lower limbs.

Time frame:
Weeks 1, 2, 4, and 12
Reported as:
Mean · percent change from baseline
Percent Change From Baseline in BSA
percent change from baselineTofacitinib 10 mg BIDPlacebo
Week 1 (n=9,3)-6.87 ± 4.97-27.80 ± 17.46
Week 2 (n=9,3)-22.51 ± 7.14-29.47 ± 19.01
Week 4 (n=9,3)-35.13 ± 10.45-34.93 ± 21.80
Week 12 (n=8,3)-77.40 ± 11.98-37.26 ± 21.53
SecondaryItch Severity Item (ISI) Score by Visit

The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single-item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends. the baseline is defined as the average of all available diary entries before Baseline/Day 1 and the in-clinic measurement on Baseline/day 1. Week 1 is the mean of daily values of study days 2 to 8 and Week 2 is the mean of daily values of study days 9 to 15.

Time frame:
Baseline and Weeks 1, 2, 4, and 12
Reported as:
Mean · units on a scale
Itch Severity Item (ISI) Score by Visit
units on a scaleTofacitinib 10 mg BIDPlacebo
Baseline (n=9,3)6.35 ± 0.893.46 ± 1.94
Week 1 (n=9,3)3.81 ± 0.973.90 ± 1.73
Week 2 (n=9,3)2.45 ± 0.911.99 ± 0.73
Week 4 (n=9,3)1.22 ± 0.572.67 ± 1.20
Week 12 (n=8,3)0.75 ± 0.626.00 ± 1.53
SecondaryChange From Baseline in ISI by Visit

ISI, a single-item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends. The baseline is defined as the average of all available diary entries before Baseline/Day 1 and the in-clinic measurement on Baseline/Day 1. Week 1 is the mean of daily values of study days 2 to 8 and Week 2 is the mean of daily values of study days 9 to 15. A negative value indicates an improvement.

Time frame:
Weeks 1, 2, 4 and 12
Reported as:
Mean · units on a scale
Change From Baseline in ISI by Visit
units on a scaleTofacitinib 10 mg BIDPlacebo
Week 1 (n=9,3)-2.55 ± 0.590.45 ± 0.52
Week 2 (n=9,3)-3.90 ± 0.67-1.47 ± 1.31
Week 4 (n=9,3)-5.13 ± 0.77-0.79 ± 2.35
Week 12 (n=8,3)-5.96 ± 0.992.54 ± 2.61
SecondaryTarget Plaque Severity Score (TPSS) by Visit

Target lesions were selected at baseline and followed for the duration of the study. Each target lesion was scored by the investigator on severity of erythema, induration, and scaling according to a 5-point (0 to 4) severity scale with a maximum sum score for a plaque of 12. The TPSS was calculated as the sum of the scores for erythema, induration, and scaling; the score can vary in increments of 1 unit from 0 to 12.

Time frame:
Baseline and Weeks 1, 2, 4, and 12
Reported as:
Mean · score on a scale
Target Plaque Severity Score (TPSS) by Visit
score on a scaleTofacitinib 10 mg BIDPlacebo
Baseline (n=9,3)8.7 ± 0.68.3 ± 0.3
Week 1 (n=9,3)7.1 ± 0.77.0 ± 1.2
Week 2 (n=9,3)6.0 ± 0.76.7 ± 1.2
Week 4 (n=9,3)4.6 ± 1.16.7 ± 1.9
Week 12 (n=8,3)2.8 ± 1.36.0 ± 1.7
SecondaryPercent Change From Baseline in TPSS by Visit

Target lesions were selected at baseline and followed for the duration of the study. Each target lesion was scored by the investigator on severity of erythema, induration, and scaling according to a 5-point (0 to 4) severity scale with a maximum sum score for a plaque of 12. The TPSS was calculated as the sum of the scores for erythema, induration, and scaling; the score can vary in increments of 1 unit from 0 to 12. A negative value indicated improvment.

Time frame:
Weeks 1, 2, 4, and 12
Reported as:
Mean · percent change from baseline
Percent Change From Baseline in TPSS by Visit
percent change from baselineTofacitinib 10 mg BIDPlacebo
Week 1 (n=9,3)-16.69 ± 7.72-16.67 ± 11.02
Week 2 (n=9,3)-29.78 ± 8.39-20.83 ± 11.02
Week 4 (n=9,3)-47.55 ± 12.40-20.83 ± 20.83
Week 12 (n=8,3)-67.28 ± 15.17-29.17 ± 18.16

Adverse events

Collected over Adverse events (AEs) were reported from the time of informed consent through and including 28 calendar days after the last administration of the investigational product.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tofacitinib 10 mg BID—0/9 (0%)2/9 (22.2%)
Placebo—1/3 (33.3%)1/3 (33.3%)
Most frequent serious events
Most frequent serious events
EventTofacitinib 10 mg BIDPlacebo
CholelithiasisHepatobiliary disorders0/91/3
Most frequent other events
Most frequent other events
EventTofacitinib 10 mg BIDPlacebo
Gravitational oedemaGeneral disorders0/91/3
LymphadenopathyBlood and lymphatic system disorders1/90/3
NasopharyngitisInfections and infestations1/90/3
PharyngitisInfections and infestations1/90/3
Tooth infectionInfections and infestations1/90/3
SyncopeNervous system disorders1/90/3
PsoriasisSkin and subcutaneous tissue disorders1/90/3

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Tofacitinib 10 mg BIDPlaceboTotal
Mean45.2 ± 11.346.7 ± 21.545.6 ± 13.3
Sex: Female, Male
Sex: Female, Male(Participants)Tofacitinib 10 mg BIDPlaceboTotal
Female224
Male718
08

Study locations

5 sites
  • Dermatology Research Associates
    Los Angeles, California 90045, United States
  • Olympian Clinical Research
    Tampa, Florida 33609, United States
  • Menter Dermatology Research Institute
    Dallas, Texas 75246, United States
  • Center for Clinical Studies
    Houston, Texas 77004, United States
  • Center for Clinical Studies
    Houston, Texas 77030, United States
09

References and documents

Publications

  • Panaccione R, Isaacs JD, Chen LA, Wang W, Marren A, Kwok K, Wang L, Chan G, Su C. Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials. Dig Dis Sci. 2021 Aug;66(8):2732-2743. doi: 10.1007/s10620-020-06560-4. Epub 2020 Aug 20. Erratum In: Dig Dis Sci. 2021 Sep;66(9):3214-3215. doi: 10.1007/s10620-020-06638-z. PubMed 32816215 ↗
  • Krueger J, Clark JD, Suarez-Farinas M, Fuentes-Duculan J, Cueto I, Wang CQ, Tan H, Wolk R, Rottinghaus ST, Whitley MZ, Valdez H, von Schack D, O'Neil SP, Reddy PS, Tatulych S; A3921147 Study Investigators. Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: A randomized phase 2 study. J Allergy Clin Immunol. 2016 Apr;137(4):1079-1090. doi: 10.1016/j.jaci.2015.12.1318. PubMed 27059729 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2013, a primary completion of Nov 2013 and a completion of Nov 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2015, 1 year 5 months after primary completion. A results delay was requested in Jan 2015.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2012
First posted
Oct 18, 2012
Start
Mar 2013
Primary completionActual
Nov 2013
CompletionActual
Nov 2013
Results delay requested
Jan 27, 2015
Results first posted
Apr 13, 2015
Last update
Apr 13, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01710046
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Oct 18, 2012
Start date
Mar 2013
Primary completion
Nov 2013
Completion
Nov 2013
Results posted
Apr 13, 2015
Last update
Apr 13, 2015

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tofacitinib

Start the discussion